Disease-modifying therapies include transthyretin stabilizers (tafamidis; Class I, Level B) and RNA silencers (patisiran/inotersen; Class IIa, Level B) for ATTR amyloidosis [25,99], as well as proteasome-inhibitor-based chemotherapy (±daratumumab; Class I, Level B) and autologous stem-cell transplant (Class IIa, Level B) for AL amyloidosis [100,101]. Here, TTR is linked to AL amyloidosis.